Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Trial Details

NCT ID

NCT05489211

Phase

PHASE2

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• Datopotamab deruxtecan (Dato-DXd)
• Capecitabine
• 5-Fluorouracil
• Volrustomig
• Carboplatin
• Bevacizumab

Locations (sample)

• Los Angeles, California, United States|34.05223,-118.24368
• San Diego, California, United States|32.71571,-117.16472
• Santa Rosa, California, United States|38.44047,-122.71443
• Muncie, Indiana, United States|40.19338,-85.38636
• Kansas City, Kansas, United States|39.11417,-94.62746

Key Eligibility Criteria

• Male and female, ≥ 18 years
• Documented advanced or metastatic malignancy
• Eastern Cooperative Oncology Group performance status of 0 or 1 with no deterioration over the 2 weeks prior to baseline or day of first dosing
• All participants must provide a tumour sample for tissue-based analysis

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.